CD133 expression has been identified within several human HCC cell lines, and recent work demonstrates a mechanistic link between TGF-β signaling and epigenetic modification as a regulator of CD133 expression within Huh7 cells, with increasing CD133 expression correlating with tumor initiation (Fig. 1).59 A prospective isolation of single

CD133+ TISCs from liver-specific Pten-deficient animals demonstrates robust tumor initiation in immune-deficient and syngenic immune-competent hosts.60 Follow-up work demonstrates that the chronic inflammatory state of the model, not the oncogenic signals resulting from Pten loss, is the primary driver of TISC formation.61 BMS 907351 EpCAM is present in the developing liver and biliary system, and is absent in mature hepatocytes.4, 62

EpCAM thus serves as a potential link between LPC and TISC populations (Fig. 1). In HCC, EpCAM expression correlates with in vivo learn more tumor initiation as well as patient survival.48, 57 CD44 expression is well characterized within breast TISC populations (CD44high/+CD24low/−).63 In HCC, CD44 expression correlates with tumor initiation, metastatic potential, and chemotherapy resistance (Fig. 1).64, 65In vitro, the inhibition of CD44 expression results in reduction of TISC characteristics.66 Because TISCs are proposed to be rare populations, one concern is the variability of CD133 and other marker expression, which ranges from less than 1% in MHCC97-H cells to 60% in Huh7 cells.37, 65 This discrepancy suggests that isolating TISCs, based on the coexpression of multiple markers, would be more effective than use of a single marker. A mechanism for deregulated signaling, resulting in specific β-catenin activation results in up-regulation of TISC surface marker EpCAM, effectively linking TISC

signaling mechanisms to surface marker expression.48 External factors, such as matrix stiffness, have also been implicated in promoting TISCs; although increasing matrix stiffness was associated with chemotherapy resistance, decreasing matrix stiffness was associated with other TISC characteristics, such as CD133 and CD44 expression.67 Alternative methods for TISC isolation include functional assays, such as side population, in which the exclusion of Hoechst dye identifies Mannose-binding protein-associated serine protease TISCs,68, 69 and aldehyde dehydrogenase activity.70 A functional assay may be superior to cell-surface markers for TISC isolation, because functional assays isolate cells based on the ability to detoxify—a key TISC characteristic.37 In terms of novel TISC-based therapies for HCC, there is a synergistic action between the histone deacetylase (HDAC) inhibitor, vorinostat, and the poly(ADP-ribose) polymerase (PARP) inhibitor, ABT1888, in HCC cell lines.71 The use of HDAC inhibitors is supported by the epigenetic modifications that enable the maintenance of the dedifferentiated state within TISC populations.